clinical trial · NCT02392130
A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
LEO Pharma·phase1·completed·n = 40
Skin Tissue DiseasesConnective Tissue DiseasesClobetasol propionate 0.05% ointmentLEO 130852A gel 1%LEO 130852A placebo gel
brief summary
The purpose of this study is to assess the effect of LEO 130852A gel 1% in maintaining skin thickness in healthy skin treated with steroid.
started
Mar 1, 2015
primary completion
Jun 1, 2015
completion
Jun 1, 2015
last updated
Feb 24, 2025
official title
A Prospective, Randomised, Investigator-Blinded, Vehicle-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol